melatonin/10..40mg:
cancer recovery forum:
20mg to 25 mg of melatonin to combat cancer?
literature on melatonin and cancer:
Here are two reviews of many previous studies.
Molecules. 2018:
Melatonin and Cancer Hallmarks.
asu.edu.jo
Melatonin can alter the effect of estrogen
in three different ways:
(1) Inhibition of steroid synthesis by gonads;
(2) downregulation of the synthesis of enzymes
involved in androgen synthesis such as aromatase;
(3) binding with estrogen receptor
to inhibit its stimulatory effect [78].
. cancer immortality (lack of apoptosis)
can be repressed by inhibiting telomerase,
mammalian target of rapamycin (mTOR),
CDK4/6, CDK 1/2/5/9, Akt and PI3K [13].
. mel's reduction of rat tumor was
associated with decreased levels of mTOR.
. mel also suppressed AKT/mTOR pathway
and decreased phosphorylation of mTOR
in some cancers.
. mel decreased some inflammation by
local inhibition of iNOS and COX-2 expression
through suppressing of p52 acetylation,
binding, and transactivation [107];
mel also inhibited NF-κB activation.
. some cancer inhibition seemed due to
mel's up-regulation proapoptotic protein Bim,
and down-regulation of COX-2 expression.
. mel's inhibition of cell migration
may involve inactivation of MMP-2 and MMP-9
in addition to down-regulation of
p38 signaling pathway [123]
or inhibiting the ERK/Rac1 pathway [124].
. mel's angiogenesis suppression
may be due to inhibition of endothelin-1
produced by solid tumors to promote
proliferation, metastasis, and angiogenesis [125].
. anti-oxidants are known to prevent cancer
by reducing DNA damage by free radicals,
but some of mel's antitumor effects come from
producing ROS [reactive oxygen species][148,149]
(creating rather than suppressing radicals).
. This second review shows that the
most dosages studied were from 20-40 mg.
Integrative Cancer Therapies 2012:
Melatonin as Adjuvant Cancer Care
With and Without Chemotherapy:
A Systematic Review and Meta-analysis
of Randomized Trials.
. studies were selected so that all participants
were provided single evening oral doses of mel
(10 mg in 1 study,
20 mg in 16 studies, and
40 mg in 4 studies).
. appears to impact estrogen metabolism
through activity as both a
selective estrogen receptor modulator,
and selective estrogen enzyme modulator;
[and that might be how it]
inhibits the growth of androgen-sensitive
prostate cancer cells; [but]
it also modulates androgen activity.
. increasing the activity of T and B lymphocytes,
monocytes, natural killer cells,
and immunoactive cytokines
(IFN [interferon]-γ, IL [interleukin]-2,
IL-6, and IL-12
) as well as promoting apoptosis
[normal cell death instead of immortality]
and inhibiting angiogenesis
[new blood vessels to feed new growth].
. found to significantly reduce occurrences of
hair loss from chemo,
anemia [common aging disorder:
low hemoglobin or red blood cells]
, asthenia[feeling tired], and
thrombocytopenia[low on platelets].
. inhibits the uptake of linoleic acid,
which prevents the formation of its metabolite
that is mitogenic [promoter of cell division];
and inhibits the formation of the
proangiogenic[blood supply growing] factor,
endothelin-1.
. possesses radioprotective effects
in part through its stimulation of
glutathione production
[when not low on selenium].
. may exert direct apoptotic effects by
blocking cell cycle progression
from the G phase to the S phase
and by increasing p53 and p21 gene expression.
. enhances the production of cytokines
IL-1, IL-2, IL-6, IL-12, IFN-γ, and TNF-α.
. most of mel's activities are thought to be
mel receptor mediated (MT#1 and MT#2).
. it is cleared rapidly, with a relatively short half-life
of between 30 and 57 minutes.
It should be noted that 90% of mel is cleared
in a single passage through the liver by
cytochrome P450 enzymes: CYP1A2, CYP1A1, and CYP1B1.
In the liver, it is metabolized to 6-hydroxy.melatonin,
conjugated to a sulfate or glucuronide,
and excreted in the urine.
some may be excreted directly through urine.
In addition to the rapid hepatic metabolism
it may also be metabolized nonenzymatically
in all the body’s cells.
. most of how mel works comes from
Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP.
Therapeutic actions of melatonin in cancer:
possible mechanisms.
Integr Cancer Ther. 2008;7:189-203.
. see also
Vijayalaxmi Thomas CRJr, Reiter RJ, Herman TS.
Melatonin: from basic research to cancer treatment clinics.
J Clin Oncol. 2002;20:2575-2601.
. Buscemi N, Vandermeer B, Hooton N, et al..
The efficacy and safety of exogenous melatonin
for primary sleep disorders: a meta-analysis.
J Gen Intern Med. 2005;20:1151-1158.
[ that paper talked about the nature of CAM
( complementary and alternative medicine ):
Despite concerns about the quality
of studies of CAM therapies,36,37
the 16 studies included in this review
were of moderate to high quality.
... However, it should be noted that
half of the studies reviewed
did not report funding source.
A limitation of our review is the
exclusion of nonEnglish language reports.
There is evidence of “reverse” publication bias,
in that negative CAM studies are
overrepresented in English-language journals
and positive CAM studies are overrepresented in
nonEnglish language journals.45 ]
anecdotes from recovery forum:
# 10 mg melatonin hasn't prevented recurrence.# take 40 mgs. Every evening.
while I have had a recurrence I am again in remission.
Not sure the role melatonin plays
but I have significantly outlived my original prognosis
so I am continuing the melatonin.
# insomnia lead to cancer:
using sleepwithmepodcast.com
to get into that 'not thinking too much'.
No comments:
Post a Comment